

GALDERMA

EST. 1981

Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement

Zug, Switzerland, July 29, 2023 – On Wednesday July 26, 2023 Ipsen informed Galderma of its intention to terminate the neuromodulator Research and Development (R&D) agreement signed in 2014, citing the retention of its rights and obligations related to its early-stage pipeline. This has no impact on the commercialization of Galderma's neuromodulator portfolio.

Galderma will continue to commercialize and supply Dysport®/Azzalure® and Alluzience® in territories, where approved and as per the commercial agreements. With its leading brands and services, Galderma remains committed to serving its healthcare professionals, consumers and patients globally.

Furthermore, Galderma is well-positioned to continue to build its neuromodulator pipeline, with proven in-house R&D capabilities in medical aesthetics and neuromodulators, having developed QM-1114 internally (RelabotulinumtoxinA) as well as the world's largest hyaluronic acid filler range, Restylane®. Galderma will continue its development and commercialization programs in the neuromodulators space. Along with Sculptra®, the first and original injectable poly-L-lactic acid collagen stimulator, Galderma's offering in neuromodulators and fillers makes for the broadest, unparalleled injectable aesthetics portfolio.

In regards to the ongoing arbitrations with Ipsen, Galderma will continue to pursue every available remedy to enforce its rights. The two International Chamber of Commerce arbitrations commenced by Galderma in July 2021 relate to: (1) the regulatory filing strategy for relabotulinumtoxinA and (2) to differing views relating to which countries form part of Ipsen's/Galderma's territories under the agreement.

With its purpose of advancing dermatology for every skin story, Galderma will continue to bring premium brands and scientific innovation to its expanding markets across injectable aesthetics, dermatological skincare and therapeutic dermatology.

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

About Galderma

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. Galderma's portfolio of flagship brands includes Restylane®, Dysport®, Azzalure®, Alluzience® and Sculptra® in Injectable Aesthetics; Soolantra®, Epiduo®, Differin®, Akliel®, Epsolay®, Twyneo®, Oracea®, Metvix®, Benzac® and Loceryl® in Therapeutic Dermatology; and Cetaphil® and Alastin Skincare® in Dermatological Skincare. For more information: www.galderma.com.